Oculis initiates second trial in ocular inflammation, pain, says H.C. Wainwright

H.C. Wainwright analyst Yi Chen reiterates a Buy rating and $29 price target on Oculis after the company announced that the Phase 3 OPTIMIZE-2 trial of OCS-01 for the treatment of inflammation and pain following cataract surgery had the first patient first visit. The initiation of the OPTIMIZE-2 trial demonstrates management’s successful execution of advancing multiple candidates/indications in mid- to late-stage clinical development with high efficiency, following FPFV in Stage 2 of the Phase 3 DIAMOND-1 trial in DME earlier this week and FPFV in the Phase 2b RELIEF trial in DED earlier this month, the analyst tells investors in a research note.